Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing

Antibody measurements play a central role in the diagnosis of many autoimmune and infectious diseases. One antibody detection technology, Luciferase Immunoprecipitation Systems (LIPS), utilizes genetically encoded recombinant luciferase antigen fusion proteins in an immunoglobulin capture format to...

Full description

Bibliographic Details
Main Authors: Peter D. Burbelo, Youngmi Ji, Michael J. Iadarola
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Biosensors
Subjects:
Online Access:https://www.mdpi.com/2079-6374/13/3/303
_version_ 1797613228225724416
author Peter D. Burbelo
Youngmi Ji
Michael J. Iadarola
author_facet Peter D. Burbelo
Youngmi Ji
Michael J. Iadarola
author_sort Peter D. Burbelo
collection DOAJ
description Antibody measurements play a central role in the diagnosis of many autoimmune and infectious diseases. One antibody detection technology, Luciferase Immunoprecipitation Systems (LIPS), utilizes genetically encoded recombinant luciferase antigen fusion proteins in an immunoglobulin capture format to generate robust antibody measurement with high diagnostic sensitivity and specificity. The LIPS technology has been highly useful in detecting antibodies for research diagnostics and the discovery of new autoantigens. The methodology of the assay requires immunoglobulin binding reagents such as protein A/G beads and washing steps to process the immune complex before antibody levels are measured by light production with a luminometer. Recently, simplified mix and read immunoassays based on split components of the nanoluciferase enzyme in a complementation format have been developed for antibody measurements without requiring immunoglobulin-capturing beads or washing steps. The mix and read immunoassays utilize two or three nanoluciferase fragments which when reconstituted via antigen-specific antibody binding generate a functional enzyme. At present, these split luciferase tests have been developed mainly for detecting SARS-CoV-2 antibodies. Here, we describe the traditional LIPS technology and compare it to the new split luciferase methodologies focusing on their technical features, strengths, limitations, and future opportunities for diagnostic research, and clinical applications.
first_indexed 2024-03-11T06:52:55Z
format Article
id doaj.art-c47fa9aa60e64447aa592983bd959eda
institution Directory Open Access Journal
issn 2079-6374
language English
last_indexed 2024-03-11T06:52:55Z
publishDate 2023-02-01
publisher MDPI AG
record_format Article
series Biosensors
spelling doaj.art-c47fa9aa60e64447aa592983bd959eda2023-11-17T09:53:28ZengMDPI AGBiosensors2079-63742023-02-0113330310.3390/bios13030303Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read TestingPeter D. Burbelo0Youngmi Ji1Michael J. Iadarola2Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 202892, USAAdeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 202892, USADepartment of Perioperative Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 202892, USAAntibody measurements play a central role in the diagnosis of many autoimmune and infectious diseases. One antibody detection technology, Luciferase Immunoprecipitation Systems (LIPS), utilizes genetically encoded recombinant luciferase antigen fusion proteins in an immunoglobulin capture format to generate robust antibody measurement with high diagnostic sensitivity and specificity. The LIPS technology has been highly useful in detecting antibodies for research diagnostics and the discovery of new autoantigens. The methodology of the assay requires immunoglobulin binding reagents such as protein A/G beads and washing steps to process the immune complex before antibody levels are measured by light production with a luminometer. Recently, simplified mix and read immunoassays based on split components of the nanoluciferase enzyme in a complementation format have been developed for antibody measurements without requiring immunoglobulin-capturing beads or washing steps. The mix and read immunoassays utilize two or three nanoluciferase fragments which when reconstituted via antigen-specific antibody binding generate a functional enzyme. At present, these split luciferase tests have been developed mainly for detecting SARS-CoV-2 antibodies. Here, we describe the traditional LIPS technology and compare it to the new split luciferase methodologies focusing on their technical features, strengths, limitations, and future opportunities for diagnostic research, and clinical applications.https://www.mdpi.com/2079-6374/13/3/303antibodyautoantibodyLIPSluciferase-based immunoassayssplit luciferase
spellingShingle Peter D. Burbelo
Youngmi Ji
Michael J. Iadarola
Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
Biosensors
antibody
autoantibody
LIPS
luciferase-based immunoassays
split luciferase
title Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
title_full Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
title_fullStr Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
title_full_unstemmed Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
title_short Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
title_sort advancing luciferase based antibody immunoassays to next generation mix and read testing
topic antibody
autoantibody
LIPS
luciferase-based immunoassays
split luciferase
url https://www.mdpi.com/2079-6374/13/3/303
work_keys_str_mv AT peterdburbelo advancingluciferasebasedantibodyimmunoassaystonextgenerationmixandreadtesting
AT youngmiji advancingluciferasebasedantibodyimmunoassaystonextgenerationmixandreadtesting
AT michaeljiadarola advancingluciferasebasedantibodyimmunoassaystonextgenerationmixandreadtesting